Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib and IMRT in soft tissue sarcoma
NCT05938374Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in soft tissue sarcoma (STS), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started May 2023; status: completed.
02
Drugs
fluzoparib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05938374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05938374.